Abstract
The prescription of hypnotics, mostly benzodiazepines, continues at a high level. One problem with their use is rebound insomnia: upon discontinuation sleep worsens compared with pretreatment levels. Factors influencing rebound include the type of subject, the duration of action of the hypnotic, the dosage and perhaps duration of treatment. The detection of rebound requires both sleep-laboratory and clinical studies with night-by-night analyses of individual patient data. This review concentrates on the newer compounds, (quazepam and zolpidem) which act selectively on subtypes of benzodiazepine receptors or bind atypically (zopiclone). It concludes that present evidence, while limited, is consistent with claims of less rebound potential than older benzodiazepine hypnotics of equivalent duration of action. Nevertheless, further rigorous studies are essential before these claims can be totally accepted.
Similar content being viewed by others
References
Adam K, Adamson L, Brezinova V, Hunter WM, Oswald I (1976) Nitrazepam: lastingly effective but trouble on withdrawal. BMJ 1:1558–1560
Adam K, Oswald I, Shapiro C (1984) Effects of loprazolam and of triazolam on sleep and overnight urinary cortisol. Psychopharmacology 82:389–394
Allen RP, Mendels J, Nevins DB, Chernik DA, Hoddes E (1987) Efficacy without tolerance or rebound insomnia for midazolam and temazepam after use for one to three months. J Clin Pharmacol 27:768–775
Anderson AA (1987) Zopiclone and nitrazepam: a multicenter placebo controlled comparative study of efficacy and tolerance in insomniac patients in general practice. Sleep 10 [suppl 1]:54–62
Ankier SI, Goa KL (1988) Quazepam. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in insomnia. Drugs 35:42–62
Besset A, Tafti M, Barthouil P, Rossi P, Billiard M (1990) Effect of zolpidem 10 mg on sleep architecture and daytime psychomotor skills in poor sleepers. 4th Annual Meeting of the Association of Professional Sleep Societies, Minneapolis
Bixler EO, Kales A, Soldatos CR, Kales JD (1977) Flunitrazepam, an investigational hypnotic drug: sleep laboratory evaluations. J Clin Pharmacol 17:569–578
Clark BG, Jue SG, Dawson GW, Ward A (1986) Loprazolam. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in insomnia. Drugs 31:500–516
Costa E, Puia G, Vicini S (1991) Impact of current developments in molecular biology on the pharmacotherapy of anxiety disorders. In: Meltzer D, Nerozzi D (eds) Current practices and future developments in the pharmacotherapy of mental disorders. Elsevier
Curran HV, Schifano F, Lader M (1991) Models of memory dysfunction? A comparison of the effects of scopolamine and lorazepam on memory, psychomotor performance and mood. Psychopharmacology 103:83–90
Dorian P, Sellers EM, Kaplan H, Hamilton C (1982) Evaluation of zopiclone physical dependence liability in normal volunteers. Int Pharmacopsychiatr 17 [suppl 2]:228–234
Dunbar GC et al. (1989) Patterns of benzodiazepine use in Great Britain as measured by a general population survey. Br J Psychiatry 155:836–841
Elie R, Prenay M, Le Morvan P, Bourgouin J (1990a) Efficacy and safety of zopiclone and triazolam in the treatment of geriatric insomniacs. Int Clin Psychopharmacol 5 [suppl 2]:39–46
Elie R, Lavoie G, Bourgouin J, Le Morvan P (1990b) Zopiclone versus flurazepam in insomnia: prolonged administration and withdrawal. Int Clin Psychopharmacol 5:279–286
Emeriau JP, Descamps A, Dechelotte P, Poch B, Harribey B, Alla P, Colle M (1988) Zolpidem and flunitrazepam: a multicenter trial in elderly hospitalized patients. In: Sauvanet JP, Lander SZ, Morselli PL (eds) Imidazopyridines in sleep disorders. Raven Press, New York, pp 317–326
Fleming JA, McClure DJ, Mayes C, Phillips R, Bourgouin J (1990) A comparison of the efficacy, safety and withdrawal effects of zopiclone and triazolam in the treatment of insomnia. Int Clin Psychopharmacol 5 [suppl 2]:29–38
Gaillot J, Le Roux Y, Houghton GW, Dreyfus JP (1987) Critical factors for pharmacokinetics of zopiclone in the elderly and in patients with liver and renal insufficiency. Sleep 10 [suppl 1]:7–21
Goa KL, Heel RC (1986) Zopiclone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an hypnotic. Drugs 32:48–65
Gillin JC, Spinweber CL, Johnson LC (1989) Rebound insomnia: A critical review. J Clin Psychopharmacol 9:161–172
Godtlibsen OB, Dreyfus JF (1980) Effect of 7.5 mg zopiclone (27.267RP) on sleep pattern in normal subjects. Waking and Sleeping 4:319–325
Greenblatt DJ, Harmatz JS, Zinny MA, Shader RI (1987) Effect of gradual withdrawal on the rebound sleep disorder after discontinuation of triazolam. New Engl J Med 317:722–728
Greenblatt DJ, Miller LG, Shader RI (1990) Neurochemical and pharmacokinetic correlates of the clinical action of benzodiazepine hypnotic drugs. Am J Med 88 [suppl 3A]:18S-24S
Guelfi JD (1990) Nouveaux psychotropes et cycles du sommeil. Ann Psychiatr 4:314–317
Herrmann WM, Kubicki St, Wober W (1988) Zolpidem: a four-week pilot polysomnographic study in patients with chronic sleep disturbances. In: Sauvanet JP, Lander SZ, Morselli PL (eds) Imidazopyridines in sleep disorders. Raven Press, New York, pp 261–278
Jovanovic UJ, Dreyfus JF (1982) Polygraphical sleep recordings in insomniac patients under zopiclone or nitrazepam. Int Pharmacopsychiatr 17 [suppl 2]:136–145
Julou L, Blanchard JC, Dreyfus JP (1985) Pharmacological and clinical studies of cyclopyrrolones: zopiclone and suriclone. Pharmacol Biochem Behav 23:653–659
Kales A (1990) Quazepam: hypnotic efficacy and side effects. Pharmacotherapy 10:1–12
Kales A, Kales JD (1984) Evaluation and treatment of insomnia. Oxford University Press, Oxford
Kales A, Bixler EO, Scharf M, Kales JD (1976) Sleep laboratory studies of flurazepam: a model for evaluating hypnotic drugs. Clin Pharmacol Ther 19:576–583
Kales A, Scharf MB, Kales JD (1978) Rebound insomnia: a new clinical syndrome. Science 201:1039–1040
Kales A, Scharf MB, Kales JD, Soldatos CR (1979) Rebound insomnia. A potential hazard following withdrawal of certain benzodiazepines. JAMA 241:1692–1695
Kales A, Bixler EO, Soldatos CR (1982a) Dose-response studies of lormetazepam: efficacy, side effects, and rebound insomnia. J Clin Pharmacol 22:520–530
Kales A, Bixler EO, Soldatos CR, Vela-Bueno A, Jacoby J, Kales JD (1982b) Quazepam and flurazepam: long-term use and extended withdrawal. Clin Pharmacol Ther 32:781–788
Kales A, Soldatos CR, Bixler E, Goff PJ, Vela-Bueno A (1983a) Midazolam: dose-response studies of effectiveness and rebound insomnia. Pharmacology 26:138–149
Kales A, Soldatos CR, Bixler EO, Kales JD (1983b) Rebound insomnia and rebound anxiety: a review. Pharmacology 24:121–137
Kales A, Bixler EO, Soldatos CR, Jacoby JA, Kales JD (1986a) Lorazepam: effects on sleep and withdrawal phenomena. Pharmacology 32:121–130
Kales A, Bixler EO, Soldatos CR, Vela-Bueno A, Jacoby J, Kales JD (1986b) Quazepam and temazepam: effects of short- and intermediate-term use and withdrawal. Clin Pharmacol Ther 39:345–352
Kales A, Bixler EO, Vela-Bueno A, Soldatos CR, Niklaus DE, Manfredi RL (1986c) Comparison of short and long half-life benzodiazepine hypnotics: triazolam and quazepam. Clin Pharmacol Ther 40:378–386
Kales A, Bixler EO, Vela-Bueno A, Soldatos CR, Manfredi RL (1987) Alprazolam: effects on sleep and withdrawal phenomena. J Clin Pharmacol 27:508–515
Kales JD, Kales A, Soldatos CR (1985) Quazepam: sleep laboratory studies of effectiveness and withdrawal. Neuropharmacology 8:S55–62
Kurtz D, Baas V, Rumbach L (1990) Effects on nocturnal sleep and daytime vigilance of zolpidem 10 mg administered during 14 nights to poor sleepers. Abstract of 1st Conference — Congress of European Sleep Research Society Strasbourg
Lader M, Frcka G (1987) Subjective effects during administration and on discontinuation of zopiclone and temazepam in normal subjects. Pharmacopsychiatry 20:67–71
Lader M, Lawson C (1987) Sleep studies and rebound insomnia: methodological problems, laboratory findings, and clinical implications. Clin Neuropharmacology 10:291–312
Lamphere J, Roehrs T, Vogel G, Koshorek G, Fortier J, Roth T (1990) The chronic efficacy of midazolam. Int Clin Psychopharmacol 5:31–39
Langer SZ, Arbilla S, Scatton B, Niddam R, Dubois A (1988) Receptors involved in the mechanism of action of zolpidem. In: Sauvanet JP, Lander SZ, Morselli PL (eds) Imidazopyridines in sleep disorders. Raven Press, New York, pp 55–70
Langley MS, Clissold SP (1988) Brotizolam. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an hypnotic. Drugs 35:104–122
Langtry HD, Benfield P (1990) Zolpidem. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 40:291–313
Lorizio A, Terzano MG, Parrino L, Cesana BM, Priorie P (1990) Zolpidem: a double-blind comparison of the hypnotic activity and safety of a 10-mg versus 20-mg dose. Curr Ther Res 47:889–898
Maggioni M, Frattola L (1988) Double-blind controlled study of the efficacy and safety of zolpidem versus flunitrazepam. In: Sauvanet JP, Lander SZ, Morselli PL (eds) Imidazopyridines in sleep disorders. Raven Press, New York, pp 386–387
Mamelak M, Csima A, Price V (1982) Effects of zopiclone on the sleep of chronic insomniacs. Int Pharmacopsychiatr 17 [suppl 2]:156–164
Mamelak M, Csima A, Buck L, Price V (1989) A comparative study on the effects of brotizolam and flurazepam on sleep and performance in the elderly. J Clin Psychopharmacol 9:260–267
Mamelak M, Csima A, Price V (1990) The effects of a single night's dosing with triazolam on sleep the following night. J Clin Pharmacol 30:549–555
McClure DJ, Walsh J, Chang H, Olah A, Wilson R, Pecknold JC (1988) Comparison of lorazepam and flurazepam as hypnotic agents in chronic insomniacs. J Clin Pharmacol 28:52–63
Mattmann P, Loepfe M, Scheitlin T, Schmidlin D, Gerne M, Strauch I, Lehmann D, Borbély AA (1982) Day-time residual effects and motor activity after three benzodiazepine hypnotics. Drug Res 32[I]:461–465
Mellinger GD, Balter MB, Uhlenhuth EH (1985) Insomnia and its treatment. Arch Gen Psychiatry 42:225–232
Mello de Paula AJ (1983) Comparative study of zopiclone and pentobarbitone as hypnotics. Pharmacology 27 [suppl 2]:188–195
Mereu G, Carcangiu G, Concas A, Passino N, Biggio G (1990) Reduction of reticulata neuronal activity by zolpidem and alpidem, two imidazopyridines with high affinity for type I benzodiazepine receptors. Eur J Pharmacol 179:339–346
Merlotti L, Roehrs T, Zorick FJ, Roth T (1991) Rebound insomnia: Duration of use and individual differences. J Clin Psychopharmacol 11:368–373
Monti JM (1989) Effect of zolpidem on sleep in insomniac patients. Eur J Clin Pharmacol 36:461–466
Morgan K (1990) Hypnotics in the elderly. What cause for concern? Drugs 10:688–696
Morgan K, Tomeny M (1988) Benzodiazepine withdrawal and rebound insomnia. Acta Psychiatr Scand 78:297–298
Morgan K, Dallsoo H, Ebrahim S, Arie T, Fentem PH (1988) Prevalence, frequency, and duration of hypnotic drug use among the elderly living at home. BMJ 296:601–602
Mouret J, Ruel D, Maillard P, Bianchi M (1990) Zopiclone versus triazolam in insomniac geriatric patients: a specific increase in delta sleep with zopiclone. Int Clin Psychopharmacol 5:47–55
Oswald I, Adam K, Borrow S, Idzikowski C (1979) The effects of two hypnotics on sleep, subjective feelings and skilled performance. In: Pussouant O, Oswald I (eds) Pharmacology of the states of alertness. Pergamon Press, Oxford, pp 51–63
Oswald I, French C, Adam K, Gilham J (1982) Benzodiazepine hypnotics remain effective for 24 weeks. BMJ 284:860–863
Pecknold J, Wilson R, Le Morvan P (1990) Long term efficacy and withdrawal of zopiclone: a sleep laboratory study. Int Clin Psychopharmacol 5 [suppl 2]:57–67
Prinz PN, Vitiello MV, Raskin MA, Thorpy MJ (1990) Geriatrics: sleep disorders and aging. New Engl J Med:520–526
Quadens OP, Hoffman G, Buytaert G (1982) Effects of zopiclone as compared to flurazepam on sleep in women over 40 years of age. Int Pharmacopsychiatr 17 [suppl 2]:146–155
Roehrs T, Zorick F, Wittig R, Roth T (1986) Dose determinants of rebound insomnia. Br J Clin Pharmacol 22:143–147
Roehrs T, Vogel G, Roth R (1990) Rebound insomnia: its determinants and significance. Am J Med 88 [suppl 3A]:395–425
Roth T, Kramer M, Roehrs T (1977) The consistency of sleep measures. In: Proceedings of the 3rd European Congress on Sleep Research, Montpellier. Karger, Basel, pp 286–288
Sauvanet JP, Maarek L, Roger M, Renaudin J, Louvel E, Orofiamma B (1988) Open long-term trials with zolpidem in insomnia. In: Sauvanet JP, Lander SZ, Morselli PL (eds) Imidazopyridines in sleep disorders. Raven Press, New York, pp 339–349
Scharf MB, Sachais BA, Mayleben DW, Fletcher K, Jennings SW (1990) A polysomnographic comparison of temazepam 15 and 30 mg with triazolam 0.125 and 0.25 mg in chronic insomnia. Curr Ther Res 18:555–567
Scharf MB, Mayleben DW, Kaffeman M, Krall R, Ochs R (1991) Dose response effects of zolpidem in normal geriatric subjects. J Clin Psychiatry 52:2:77–83
Schlich D, L'Heritier C, Coquelin JP, Attali P (1991) Long-term treatment of insomnia with zolpidem: a multicentre general practitioner study of 107 patients. J Int Med Res 19:271–279
Schneider-Helmert D (1988) Why low-dose benzodiazepine-dependent insomniacs can't escape their sleeping pills. Acta Psychiatr Scand 78:706–711
Shaw SH (1988) Double-blind, comparative study of zolpidem and placebo in the treatment of insomnia in elderly psychiatric in-patients. In: Sauvanet JP, Lander SZ, Morselli PL (eds) Imidazopyridines in sleep disorders. Raven Press, New York, p 389
Spinweber CL, Johnson LC (1982) Effects of triazolam (0.5 mg) on sleep, performance, memory, and arousal threshold. Psychopharmacology 76:5–12
Tham TCK, Brown H, Taggart HMcA (1989) Temazepam withdrawal in elderly hospitalized patients: a double blind randomised trial comparing abrupt versus gradual withdrawal. Int J Med Sci, 12:294–296
Tiberge M, Calvet U, Khayi N, Delahaye C, Arbus L (1988) Comparaison des effets de la zopiclone et du triazolam sur le sommeil du sujet sain. L'Encéphale 14:319–324
Trifiletti RR, Snyder SH (1984) Anxiolytic cyclopyrrolones zopiclone and suriclone bind to a novel site linked allosterically to benzodiazepine receptors. Mol Pharmacol 26:458–469
US Department of Health Education and Welfare (1977) Guidelines for the clinical evaluation of hypnotic drugs. US Government Printing Office, Washington DC
Vogel G, Scharf M, Walsh J, Roth T (1989) Effects of chronically administered zolpidem on the sleep of healthy insomniacs. Sleep Res 18:80
Wheatley D (1988) Zolpidem and placebo: a study in general practice in patients suffering from insomnia. In: Sauvanet JP, Lander SZ, Morselli PL (eds) Imidazopyridines in sleep disorders. Raven Press, New York, pp 305–316
Wickstrom E, Barbo SE, Dreyfus JF, Jerke D, Kleiven R, Slattbrekk R, Stray Tonnesen JN (1983) A comparative study of zopiclone and flunitrazepam in insomniacs seen by general practitioners. Pharmacology 27 [suppl 2]:165–172
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lader, M. Rebound insomnia and newer hypnotics. Psychopharmacology 108, 248–255 (1992). https://doi.org/10.1007/BF02245108
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02245108